Electroporation: A promising method for the nonviral delivery of DNA vaccines in humans?

Drug News and Perspectives

Volumn 23, Issue 10, 2010, Pages 647-653

  Frelin, Lars ^a   Braß, Anette ^a   Ahlén, Gustaf ^a   Brenndörfer, Erwin Daniel ^a   Chen, Margaret ^a   Sällberg, Matti ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; HEPATITIS C VACCINE; NAKED DNA; UNCLASSIFIED DRUG; VGC 3100;

ANTIGEN EXPRESSION; BIOLISTIC TRANSFORMATION; CLINICAL TRIAL (TOPIC); DNA IMMUNIZATION; ELECTROPORATION; GENE GUN; HEPATITIS C; HOST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NEEDLE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; SYRINGE; TECHNIQUE; VERRUCA VULGARIS; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; IMMUNOLOGY; METHODOLOGY; MOUSE; PHARMACEUTICS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ELECTROPORATION; HUMANS; MICE; TECHNOLOGY, PHARMACEUTICAL; VACCINES, DNA;

EID: 79954445262     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.10.1513492     Document Type: Review

References (73)

1. Ulmer, J.B., Donnelly, J.J., Parker, S.E. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(5102): 1745-9.
2. Wang, B., Ugen, K.E., Srikantan, V. et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993, 90(9): 4156-60.
3. MacGregor, R.R., Boyer, J.D., Ugen, K.E. et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998, 178(1): 92-100.
4. Wang, R., Doolan, D.L., Le, T.P. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282(5388): 476-80.
5. Catanzaro, A.T., Koup, R.A., Roederer, M. et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006, 194(12): 1638-49.
6. Catanzaro, A.T., Roederer, M., Koup, R.A. et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007, 25(20): 4085-92.
7. Graham, B.S., Koup, R.A., Roederer, M. et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194(12): 1650-60.
8. Martin, J.E., Louder, M.K., Holman, L.A. et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008, 26(50): 6338-43.
9. Martin, J.E., Pierson, T.C., Hubka, S. et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007, 196(12): 1732-40.
10. Martin, J.E., Sullivan, N.J., Enama, M.E. et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13(11): 1267-77.
11. Tavel, J.A., Martin, J.E., Kelly, G.G. et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 2007, 44(5): 601-5.
12. Gorse, G.J., Baden, L.R., Wecker, M. et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2008, 26(2): 215-23.
13. Ahlen, G., Soderholm, J., Tjelle, T.E. et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ cells. J Immunol 2007, 179(7): 4741-53.
14. Kutzler, M.A., Weiner, D.B. DNA vaccines: ready for prime time? Nat Rev Genet 2008, 9(10): 776-88.
15. Davis, B.S., Chang, G.J., Cropp, B. et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001, 75(9): 4040-7.
16. Liu, F., Song, Y., Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999, 6(7): 1258-66.
17. Zhang, G., Gao, X., Song, Y.K. et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 2004, 11(8): 675-82.
18. Epstein, J.E., Gorak, E.J., Charoenvit, Y. et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 2002, 13(13): 1551-60.
19. Williams, J., Fox-Leyva, L., Christensen, C. et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 2000, 18(18): 1939-43.
20. Trimble, C., Lin, C.T., Hung, C.F. et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003, 21(25-26): 4036-42.
21. Rao, S.S., Gomez, P., Mascola, J.R. et al. Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model. Vaccine 2006, 24(3): 367-73.
22. Hallermalm, K., Johansson, S., Brave, A. et al. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer. Scand J Immunol 2007, 66(1): 43-51.
23. Brave, A., Boberg, A., Gudmundsdotter, L. et al. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther 2007, 15(9): 1724-33.
24. Klein, T.M., Wolf, E.D., Wu, R., Sanford, C.J. High-velocity microprojectiles for delivering nucleic acids into living cells. Nature 1987, 327: 70-3.
25. Tang, D.C., DeVit, M., Johnston, S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356(6365): 152-4.
26. Feltquate, D.M., Heaney, S., Webster, R.G., Robinson, H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997, 158(5): 2278-84.
27. Frelin, L., Alheim, M., Chen, A. et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther 2003, 10(8): 686-99.
28. Nakano, I., Maertens, G., Major, M.E. et al. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 1997, 71(9): 7101-9.
29. Schirmbeck, R., Reimann, J. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12. Intervirology 2001, 44(2-3): 115-23.
30. Weiss, R., Scheiblhofer, S., Freund, J., Ferreira, F., Livey, I., Thalhamer, J. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that overrules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 2002, 20(25-26): 3148-54.
31. Nystrom, J., Chen, A., Frelin, L. et al. Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes. J Infect Dis 2010, 201(12): 1867-79.
32. Roy, M.J., Wu, M.S., Barr, L.J. et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000, 19(7-8): 764-78.
33. Neumann, E., Rosenheck, K. Permeability changes induced by electric impulses in vesicular membranes. J Membr Biol 1972, 10(3): 279-90.
34. Heller, R., Jaroszeski, M.J., Glass, L.F. et al. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer 1996, 77(5): 964-71.
35. Aihara, H., Miyazaki, J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998, 16(9): 867-70.
36. Mathiesen, I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999, 6(4): 508-14.
37. Rols, M.P., Delteil, C., Golzio, M., Dumond, P., Cros, S., Teissie, J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998, 16(2): 168-71.
38. Babiuk, S., Baca-Estrada, M.E., Foldvari, M., Middleton, D.M., Rabussay, D., Widera, G., Babiuk, L.A. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 2004, 110(1): 1-10.
39. Luckay, A., Sidhu, M.K., Kjeken, R. et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81(10): 5257-69.
40. Daud, A.I., DeConti, R.C., Andrews, S. et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008, 26(36): 5896-903.
41. Tjelle, T.E., Salte, R., Mathiesen, I., Kjeken, R. A novel electroporation device for gene delivery in large animals and humans. Vaccine 2006, 24(21): 4667-70.
42. Luxembourg, A., Hannaman, D., Ellefsen, B., Nakamura, G., Bernard, R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 2006, 24(21): 4490-3.
43. Babiuk, S., Baca-Estrada, M.E., Foldvari, M. et al. Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin. Mol Ther 2003, 8(6): 992-8.
44. Heller, L.C., Jaroszeski, M.J., Coppola, D., Heller, R. Comparison of electrically mediated and liposome-complexed plasmid DNA delivery to the skin. Genet Vaccines Ther 2008, 6: 16.
45. Heller, L.C., Jaroszeski, M.J., Coppola, D., McCray, A.N., Hickey, J., Heller, R. Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther 2007, 14(3): 275-80.
46. Choi, S.O., Kim, Y.C., Park, J.H. et al. An electrically active microneedle array for electroporation. Biomed Microdevices 2009, 12(2): 263-73.
47. Heller, R., Cruz, Y., Heller, L.C., Gilbert, R.A., Jaroszeski, M.J. Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array. Hum Gene Ther 2010, 21(3): 357-62.
48. Roos, A.K., Eriksson, F., Walters, D.C., Pisa, P., King, A.D. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther 2009, 17(9): 1637-42.
49. Roos, A.K., Eriksson, F., Timmons, J.A. et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS ONE 2009, 4(9): e7226.
50. Safety study of DNA vaccine delivered by intradermal electroporation to treat colorectal cancer (El-porCEA) (NCT01064375). ClinicalTrials.gov Web site, Accessed November 24, 2010.
51. Dean, D.A. Import of plasmid DNA into the nucleus is sequence specific. Exp Cell Res 1997, 230(2): 293-302.
52. Branden, L.J., Mohamed, A.J., Smith, C.I. A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol 1999, 17(8): 784-7.
53. Prausnitz, M.R., Mikszta, J.A., Cormier, M., Andrianov, A.K. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009, 333: 369-93.
54. Gill, H.S., Soderholm, J., Prausnitz, M.R., Sallberg, M. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther 2010, 17(6): 811-4.
55. Hegge, J.O., Wooddell, C.I., Zhang, G. et al. Evaluation of hydrodynamic limb vein injections in nonhuman primates. Hum Gene Ther 2010, 21(7): 829-42.
56. Lyckade prekliniska resultat leder till att Tripep patentsöker ny injektionsnål för DNA-vaccination på människa [news release]. CronTech Pharma, December 17, 2009. http://chrontech.se/sv/press-och- nyheter/pressmeddelanden/?id=2009121720500. Accessed November 24, 2010.
57. Low, L., Mander, A., McCann, K. et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009, 20(11): 1269-78.
58. Bowen, D.G., Walker, C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436(7053): 946-52.
59. Klade, C.S., Wedemeyer, H., Berg, T. et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008, 134(5): 1385-95.
60. Alvarez-Lajonchere, L., Shoukry, N.H., Gra, B. et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2008, 16(3): 156-67.
61. Nevens, F., Roskams, T., Van Vlierberghe, H. et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003, 38(5): 1289-96.
62. Folgori, A., Capone, S., Ruggeri, L. et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006, 12(2): 190-7.
63. Immunotherapy with TG4040 in treatment-naïve patients chronically infected with hepatitis C virus (NCT00529321). ClinicalTrials.gov Web site, Accessed November 24, 2010.
64. Efficacy of the therapeutic vaccine TG4040 combined with pegylated interferon and ribavirin in chronic HCV patients (HCVac) (NCT01055821). ClinicalTrials.gov Web site, Accessed November 24, 2010.
65. A study of a new candidate vaccine against hepatitis C virus (HCV) (NCT01070407). ClinicalTrials.gov Web site, Accessed November 24, 2010.
66. Study of a novel therapeutic vaccine for hepatitis C virus (NCT01094873). ClinicalTrials.gov Web site, Accessed November 24, 2010.
67. Phase I/IIa dose ranging CHRONVAC-C(R) study in chronic HCV patients (NCT00563173). ClinicalTrials.gov Web site, Accessed November 24, 2010.
68. Inchauspe, G., Honnet, G., Bonnefoy, J.Y., Nicosia, A., Strickland, G.T. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008, 8(12): 739-40.
69. Sallberg, M., Diepolder, H., Jung, M.C. et al. Antiviral effects of therapeutic vaccination with naked DNA delivered by in vivo electroporation in patients with chronic hepatitis C. Hepatology 2008, 48(Suppl.): 1022A-3A.
70. Kenter, G.G., Welters, M.J., Valentijn, A.R. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361(19): 1838-47.
71. Inovio Biomedical cervical cancer therapeutic vaccine generates dose-related immune response in clinical trial [news release]. Inovio Pharmaceuticals, February 8, 2010. http://phx.corporate-ir.net/phoenix.zhtml?c= 105128&p=irol-newsArticle&ID=1384705&highlight=. Accessed November 24, 2010.
72. Inovio Pharmaceuticals achieves unprecedented T-cell immune responses in human trial of DNA vaccine for cervical dysplasia and cancer caused by HPV [news release]. Inovio Pharmaceuticals, September 13, 2010. http://phx.corporate-ir. net/phoenix.zhtml?c=105128&p=irol-newsArticle&ID=1469951&highlight=. Accessed November 24, 2010.
73. Fourth dose of human papillomavirus (HPV) DNA plasmid (VGX-3100) + EP in adult females previously vaccinated with three doses of VGX-3100 (NCT01188850). ClinicalTrials. gov Web site, Accessed November 24, 2010.